The French company “Akticor Biotech” published the results of a study showing the effectiveness of a new drug in reducing… Stroke deathsThe drug's name is “glinzosimab”, and the study was published in Lancet Neuroscience.
A stroke is a serious condition in which the blood supply to part of the brain stops or decreases significantly, leading to an interruption of its supply of oxygen and nutrients. Within minutes, brain cells begin to die, and because these cells do not regenerate, this may lead to permanent damage to the brain.
There are 3 types of strokes: ischemic stroke, which results from interruption of blood supply to the brain as a result of blockage of one of the arteries leading to it. This is the result of a blood clot that may form in the brain or come from another place in the body, such as the heart.
The second type is hemorrhagic stroke, which occurs due to bleeding in one of the brain vessels. The third type is transient ischemic stroke, which is a type of temporary stroke that occurs as a result of an interruption or temporary decrease in the brain’s blood supply, and lasts for at least 5 minutes, and then The blood supply returns to normal so no permanent brain damage occurs.
The researchers evaluated glenzosimab compared with conventional treatment (thrombolysis with or without thrombectomy) in patients with acute stroke.
Thrombolysis therapy is a procedure that uses medication or a minor surgical procedure to break up blood clots and prevent new ones from forming.
Thrombectomy treatment is surgery to remove a blood clot from a blood vessel: an artery or vein.
More severe strokes
Patients with the most severe strokes and the highest risk of intracranial bleeding are the best responders to this treatment, the researchers said.
Researcher Dr. Mikael Mazighi said, “This is the first time that a randomized clinical trial evaluating an anticoagulant agent during the acute phase of ischemic stroke has demonstrated a significant effect. This is very likely attributable to a reduction in the number of symptomatic intracerebral hemorrhages.”
“This achievement paves the way for new treatments for patients in the acute phase of stroke,” he added.